Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
2023–2024 Article Series of the Canadian Association of General Practitioners...
share announcement

2023–2024 Article Series of the Canadian Association of General Practitioners in Oncology

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 31 December 2024 | Viewed by 14989

Special Issue Editor

Dr. Genevieve Chaput

E-Mail Website
Guest Editor
McGill University Health Centre, Division of Oncology and Family Medicine, McGill University, Montreal, QC H8S 3N5, Canada
Interests: cancer survivorship; communication in healthcare; palliative medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Canadian Association of General Practitioners in Oncology (CAGPO) is pleased to continue its partnership with Current Oncology for their fourth 2023–2024 article series targeting health professionals involved in oncology and palliative care. Stay tuned for what will surely be another excellent six-article educational series with the contributions of recognized experts on the latest cancer and supportive care topics.

Dr. Genevieve Chaput
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (7 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Review, Other

2 pages, 178 KiB  
Editorial
Oncology Workforce Crisis: Let’s Work Smarter, Not Harder
by Genevieve Chaput
Curr. Oncol. 2023, 30(12), 10408-10409; https://doi.org/10.3390/curroncol30120758 - 11 Dec 2023
Cited by 1 | Viewed by 1303
Abstract
Editorial: Cancer projections in Canada are bleak, with the average annual number of new cancer diagnoses expected to be 79% higher in 2028–2032 compared to 2003–2007 [...] Full article
(This article belongs to the Special Issue 2023–2024 Article Series of the Canadian Association of General Practitioners in Oncology)

Review

Jump to: Editorial, Other

14 pages, 460 KiB  
Review
COVID-19 and Cancer Care: A Review and Practical Guide to Caring for Cancer Patients in the Era of COVID-19
by Simon Claveau, Farhan Mahmood, Baraa Amir, Jennifer Jing Wah Kwan, Cheryl White, Joe Vipond and Lisa Iannattone
Curr. Oncol. 2024, 31(9), 5330-5343; https://doi.org/10.3390/curroncol31090393 - 10 Sep 2024
Viewed by 2292
Abstract
COVID-19, a novel infectious disease caused by the emergence of the SARS-CoV-2 virus in 2020, has had a profound impact on healthcare, both at the individual and population level. The impact at the population level was felt most acutely during the emergency phase [...] Read more.
COVID-19, a novel infectious disease caused by the emergence of the SARS-CoV-2 virus in 2020, has had a profound impact on healthcare, both at the individual and population level. The impact at the population level was felt most acutely during the emergency phase of the pandemic, with hospital capacity issues leading to widespread disruptions and delays in the delivery of healthcare services such as screening programs and elective surgeries. While hospitals are no longer being acutely overwhelmed by COVID-19 patients, the impact of the virus on vulnerable patient populations such as cancer patients continues to be of ongoing consequence. Cancer patients remain at high risk of hospitalization, ICU admission, and death due to COVID-19, even in the era of vaccination. Infection prevention and risk mitigation strategies such air quality control, masking, testing, vaccination, and treatment should therefore be integrated into the usual care and counseling of cancer patients moving forward to avoid preventable morbidity and mortality from this infection and ensure the safety of this vulnerable cohort as they navigate their cancer diagnosis and treatment in the era of COVID-19. Full article
(This article belongs to the Special Issue 2023–2024 Article Series of the Canadian Association of General Practitioners in Oncology)
►▼ Show Figures

Figure 1

23 pages, 809 KiB  
Review
Contemporary Management of Renal Cell Carcinoma: A Review for General Practitioners in Oncology
by Anish Tejura, Ricardo Fernandes, Stacey Hubay, Matthew Scott Ernst, Mario Valdes and Anupam Batra
Curr. Oncol. 2024, 31(8), 4795-4817; https://doi.org/10.3390/curroncol31080359 - 22 Aug 2024
Viewed by 3080
Abstract
Renal cell carcinoma accounts for a significant proportion of cancer diagnoses in Canadians. Over the past several years, the management of renal cell cancers has undergone rapid changes in all prognostic risk categories, resulting in improved oncologic outcomes. Novel strategies for metastatic disease [...] Read more.
Renal cell carcinoma accounts for a significant proportion of cancer diagnoses in Canadians. Over the past several years, the management of renal cell cancers has undergone rapid changes in all prognostic risk categories, resulting in improved oncologic outcomes. Novel strategies for metastatic disease make use of the synergy between checkpoints and angiogenesis inhibition. Moreover, combination checkpoint inhibition has demonstrated durable efficacy in some patients. Adjuvant immunotherapy has recently shown a survival benefit for the first time in select cases. Significant efforts are underway to explore new compounds or combinations for later-line diseases, such as inhibitors of hypoxia-inducible factors and radiolabeled biomolecules targeting tumor antigens within the neoplastic microenvironment for precise payload delivery. In this manuscript, we provide a comprehensive review of the available data addressing key therapeutic areas pertaining to systemic therapy for metastatic and localized disease, review the most relevant prognostic tools, describe local therapies and management of CNS disease, and discuss practice-changing trials currently underway. Finally, we focus on some of the practical aspects for general practitioners in oncology caring for patients with renal cell carcinoma. Full article
(This article belongs to the Special Issue 2023–2024 Article Series of the Canadian Association of General Practitioners in Oncology)
►▼ Show Figures

Graphical abstract

12 pages, 254 KiB  
Review
Gastro-Intestinal Symptoms in Palliative Care Patients
by Golda Elisa Tradounsky
Curr. Oncol. 2024, 31(4), 2341-2352; https://doi.org/10.3390/curroncol31040174 - 21 Apr 2024
Viewed by 2219
Abstract
This review of the palliation of various gastro-intestinal (GI) symptoms encountered in cancer patients is by no means exhaustive. Frequent symptoms such as constipation, nausea and vomiting, bowel obstructions, ascites and bleeds will be discussed, focusing on their assessment and most importantly, how [...] Read more.
This review of the palliation of various gastro-intestinal (GI) symptoms encountered in cancer patients is by no means exhaustive. Frequent symptoms such as constipation, nausea and vomiting, bowel obstructions, ascites and bleeds will be discussed, focusing on their assessment and most importantly, how to control the associated symptoms. All of these symptoms and GI complications can significantly impact patients’ quality of life (QOL) and should be treated as quickly and aggressively as possible. Full article
(This article belongs to the Special Issue 2023–2024 Article Series of the Canadian Association of General Practitioners in Oncology)
16 pages, 1516 KiB  
Review
Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology
by Anupam Batra, Daniel Glick and Mario Valdes
Curr. Oncol. 2024, 31(2), 1047-1062; https://doi.org/10.3390/curroncol31020078 - 15 Feb 2024
Cited by 4 | Viewed by 2780
Abstract
Prostate cancer accounts for a significant proportion of cancer diagnoses in Canadian men. Over the past decade, the therapeutic landscape for the management of metastatic prostate cancer has undergone rapid changes. Novel strategies use hormonal agents, chemotherapy, homologous recombination repair inhibitors, and radioligand [...] Read more.
Prostate cancer accounts for a significant proportion of cancer diagnoses in Canadian men. Over the past decade, the therapeutic landscape for the management of metastatic prostate cancer has undergone rapid changes. Novel strategies use hormonal agents, chemotherapy, homologous recombination repair inhibitors, and radioligand therapy or combination strategies in addition to androgen deprivation therapy. In this review, we summarize the available data addressing key therapeutic areas along the disease continuum and focus on practical aspects for general practitioners in oncology managing patients with metastatic prostate cancer. Full article
(This article belongs to the Special Issue 2023–2024 Article Series of the Canadian Association of General Practitioners in Oncology)
►▼ Show Figures

Figure 1

Other

Jump to: Editorial, Review

6 pages, 1413 KiB  
Commentary
Simplifying Serious Illness Communication: Preparing or Deciding
by Jeff Myers, Leah Steinberg, Nadia Incardona, Jessica Simon, Justin Sanders and Hsien Seow
Curr. Oncol. 2024, 31(10), 5832-5837; https://doi.org/10.3390/curroncol31100433 - 28 Sep 2024
Viewed by 816
Abstract
Clinicians have a sincere desire to ensure that the decision-making processes of seriously ill patients are well informed throughout illness trajectories. A quagmire of variable terminology (e.g., advance care planning, serious illness conversations, goals-of-care discussions, etc.), however, currently predominates the field of serious [...] Read more.
Clinicians have a sincere desire to ensure that the decision-making processes of seriously ill patients are well informed throughout illness trajectories. A quagmire of variable terminology (e.g., advance care planning, serious illness conversations, goals-of-care discussions, etc.), however, currently predominates the field of serious illness communication. This creates uncertainty among clinicians as to the overall purpose, tasks, and specific outcomes of conversations that address serious illness. The Preparing or Deciding model is a unifying framework that provides conceptual clarity by helping clinicians understand their role in leading these important conversations. The Preparing or Deciding model simply posits that conversations with seriously ill patients are about either preparing or deciding. It considers these tasks to be mutually exclusive, which can help bypass many of the barriers to having these conversations. The Preparing or Deciding model compliments all existing resources and frameworks and is applicable to all healthcare practitioners in every care setting. To help move forward serious illness communication education and research, as well as process improvement efforts more effectively, here, we describe the Preparing or Deciding model. Full article
(This article belongs to the Special Issue 2023–2024 Article Series of the Canadian Association of General Practitioners in Oncology)
►▼ Show Figures

Figure 1

7 pages, 203 KiB  
Commentary
A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine
by Mariana Pilon Capella and Khashayar Esfahani
Curr. Oncol. 2024, 31(4), 1913-1919; https://doi.org/10.3390/curroncol31040143 - 2 Apr 2024
Viewed by 1768
Abstract
In the past decade, a lot of insight was gathered into the composition of the host and tumor factors that promote oncogenesis and treatment resistance. This in turn has led to the ingenious design of multiple new classes of drugs, which have now [...] Read more.
In the past decade, a lot of insight was gathered into the composition of the host and tumor factors that promote oncogenesis and treatment resistance. This in turn has led to the ingenious design of multiple new classes of drugs, which have now become the new standards of care in cancer therapy. These include novel antibody-drug conjugates, chimeric antigen receptor T cell therapies (CAR-T), and bispecific T cell engagers (BitTE). Certain host factors, such as the microbiome composition, are also emerging not only as biomarkers for the response and toxicity to anti-cancer therapies but also as potentially useful tools to modulate anti-tumor responses. The field is slowly moving away from one-size-fits-all treatment options to personalized treatments tailored to the host and tumor. This commentary aims to cover the basic concepts associated with these emerging therapies and the promises and challenges to fight cancer. Full article
(This article belongs to the Special Issue 2023–2024 Article Series of the Canadian Association of General Practitioners in Oncology)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-7
Back to TopTop